Compugen reported its second quarter 2026 results today.
In a clinical-stage biotech, the quarterly numbers are almost never the story. A company like this is not measured by profit - it is measured by two things: how long its cash lasts, and when the next data point arrives. We will start with the numbers and move quickly to what matters.
What was reported
| Q2 2026 | Q2 2025 | |
|---|---|---|
| Revenue | $2.6 million | $1.3 million |
| R&D | $6.3 million | $5.6 million |
| G&A | $2.3 million | $2.2 million |
| Net loss | $7.0 million ($0.07/share) | $7.3 million ($0.08/share) |
Revenue doubled, and it must not be read as sales. Per the company's release, revenue in both quarters reflects recognition of portions of both the upfront payment and the IND milestone payment from the licence agreement with Gilead. This is the accounting spread of money already received, not new demand.
The expenses tell a simple story: R&D rose 12.5%, and G&A barely moved. That is the behaviour of a company pushing money into trials rather than into overhead.
The balance sheet, and this is the important part
$125.3 million in cash, cash equivalents, short-term bank deposits and marketable securities as of 30 June 2026. The company has no debt at all.
The company states that these balances are expected to fund its operating plans "into 2029" - and that does not include any additional future inflows.
The gap worth stopping on
Here is a simple calculation worth holding in mind.
Compugen's market capitalisation stands at roughly $208 million. On its balance sheet sit $125.3 million of cash, with no debt.
That means the market is pricing the company's entire clinical pipeline at about $83 million.
Three assets go into that number: an antibody in a randomised placebo-controlled trial, potential royalties and milestones from an asset sitting in 12 AstraZeneca Phase 3 trials, and a second asset in Phase 1 at Gilead.
This does not mean the company is cheap. In clinical-stage biotech, a low valuation usually reflects a low probability the market assigns to success, not a forgotten opportunity. But it does mean the number is small, and that volatility in both directions is the default here - any meaningful data readout can move it sharply.
The pipeline: three assets, three levels of maturity
COM701 - the asset the company leads itself
This is the inflection point, and this is what belongs in the calendar.
COM701 is an anti-PVRIG antibody, potentially first-in-class. It is being evaluated in the MAIA-ovarian trial - a randomised, placebo-controlled adaptive platform trial, as maintenance monotherapy in patients with relapsed platinum-sensitive ovarian cancer in the second and third line.
What makes this interesting is the definition of the population: per the company, this is a setting with no approved treatment option at all. A company aiming at a window with no competing therapy is measured against placebo, and that is a lower bar than beating an existing treatment.
The date: an interim analysis with median progression-free survival data, expected by the first quarter of 2027.
During the quarter the company presented a trial-in-progress poster at the ESMO Gynaecological Cancers Congress in Copenhagen. The rationale presented there: the PVRIG pathway is biologically differentiated from other checkpoints such as PD-1 and TIGIT, it is highly expressed in ovarian cancer, and durable responses to COM701 have previously been observed in heavily pre-treated patients.
Per the company, a clear prolongation of progression-free survival versus placebo could inform a registration path for the drug.
Rilvegostomig - AstraZeneca's asset
This is a PD-1/TIGIT bispecific antibody developed by AstraZeneca, whose TIGIT component derives from Compugen's COM902 programme.
At ASCO 2026 AstraZeneca presented an updated analysis from the GEMINI-Hepatobiliary study, in combination with chemotherapy in the first-line setting. This was the first overall survival readout for the drug: a median of 16.8 months, against less than 13 months in historical first-line biliary tract cancer trials.
A caveat the company itself notes and which should not be skipped: longer follow-up and randomised data from the ongoing Phase 3 trial will be needed to validate the findings. A comparison to historical trials is not a substitute for a control arm.
AstraZeneca is advancing the drug across 12 ongoing Phase 3 trials, and recently initiated another in combination with Datroway in urothelial carcinoma.
GS-0321 - Gilead's asset
Formerly COM503. An antibody blocking the interaction between IL-18 binding protein and IL-18, licensed to Gilead. The Phase 1 dose-escalation trial continues to progress as planned. The report contains no new data beyond that.
Management, and the context worth mentioning
The quotes in the release are attributed to Eran Ophir, Ph.D., President and CEO. It is worth clarifying that this is not a new change: Ophir, previously Chief Scientific Officer, took the role in September 2025, succeeding Anat Cohen-Dayag, Ph.D., who led the company from 2010 and moved to the role of Executive Chair.
The company describes itself as a pioneer in computational drug target discovery, and credits its AI/ML-powered Unigen platform with discovering the targets of all three assets - COM701, COM902 and GS-0321.
What to understand before reading this as an AI story
An AI-powered discovery platform produces biological targets, not approved drugs. The distance between an identified target and a drug that sells is measured in a decade and in billions, and most targets never get there. Compugen's platform has demonstrated that it produces assets large pharmaceutical companies are willing to license - and that is a real achievement - but none of the three assets has been approved for marketing.
A note on the share price
Compugen closed at $2.38, up 1.28%.
And it is worth pausing on that: during the session the stock traded down more than 6%. A reversal of more than seven points within a single day. This is precisely why a stock's reaction to a report is measured at the close rather than intraday - a figure taken mid-session would have told the opposite story here.
My Angle
A personal opinion of Ilan Abramov - not advice, not a recommendation
In a company like this I try to ignore the bottom line almost entirely. A $7 million quarterly loss is not news - it is a description of what a clinical-stage company does. Profit, if it comes, will come years from now and in a single jump.
What does interest me here is a combination of three things.
The first is the runway. Cash into 2029, with no debt, is a real asset in an industry where companies are forced to raise at bad prices precisely when they need it most.
The second is the date. An interim analysis by the first quarter of 2027 is a defined data point, not a general promise. In biotech that is the difference between a thesis and a story.
And the third is the gap between $125 million of cash and a $208 million market cap. It says the market is pricing the pipeline very cheaply. But I am careful about calling that an opportunity - in biotech, a low valuation is usually a probability estimate rather than a mistake.
What I do take from it: this is a stock where a single data point can change the entire picture, in either direction. Anyone entering one of these should know they are buying a binary outcome, not a business.
